MX2013005994A - Monobactamas. - Google Patents

Monobactamas.

Info

Publication number
MX2013005994A
MX2013005994A MX2013005994A MX2013005994A MX2013005994A MX 2013005994 A MX2013005994 A MX 2013005994A MX 2013005994 A MX2013005994 A MX 2013005994A MX 2013005994 A MX2013005994 A MX 2013005994A MX 2013005994 A MX2013005994 A MX 2013005994A
Authority
MX
Mexico
Prior art keywords
monobactams
directed
present
bacterial infections
new class
Prior art date
Application number
MX2013005994A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Frank Brown
Mark Stephen Plummer
Veerabahu Shanmugasundaram
Hud Lawrence Risley
Mark J Mitton-Fry
Seungil Han
Manjinder Lall
Jeremy T Starr
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2013005994A publication Critical patent/MX2013005994A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2013005994A 2010-11-29 2011-11-15 Monobactamas. MX2013005994A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41757510P 2010-11-29 2010-11-29
PCT/IB2011/055104 WO2012073138A1 (en) 2010-11-29 2011-11-15 Monobactams

Publications (1)

Publication Number Publication Date
MX2013005994A true MX2013005994A (es) 2013-07-15

Family

ID=45315854

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005994A MX2013005994A (es) 2010-11-29 2011-11-15 Monobactamas.

Country Status (17)

Country Link
US (3) US20120302542A1 (enExample)
EP (1) EP2646436B1 (enExample)
JP (1) JP5777725B2 (enExample)
KR (1) KR101514587B1 (enExample)
CN (1) CN103228652B (enExample)
AR (1) AR084001A1 (enExample)
AU (1) AU2011336209B2 (enExample)
CA (1) CA2815821C (enExample)
DK (1) DK2646436T3 (enExample)
ES (1) ES2542431T3 (enExample)
IL (1) IL226052A0 (enExample)
MX (1) MX2013005994A (enExample)
SG (1) SG190007A1 (enExample)
TW (1) TW201247661A (enExample)
UY (1) UY33754A (enExample)
WO (1) WO2012073138A1 (enExample)
ZA (1) ZA201304479B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015099107A1 (ja) 2013-12-26 2015-07-02 塩野義製薬株式会社 含窒素6員環誘導体およびそれらを含有する医薬組成物
SMT201900218T1 (it) 2014-03-24 2019-05-10 Novartis Ag Composti organici di monobattami, per il trattamento di infezioni batteriche
EA037569B1 (ru) 2015-09-23 2021-04-15 Новартис Аг Соли монобактамного антибиотика и их применение
CN105481812B (zh) * 2015-11-30 2020-04-21 重庆天奕恒化科技有限公司 一种5-苄氧基-4-氧代-4h-吡喃-2-羧酸的制备方法
KR20180093925A (ko) * 2015-12-15 2018-08-22 머크 샤프 앤드 돔 코포레이션 박테리아 감염을 치료하기 위한 비아릴 모노박탐 화합물 및 그의 사용 방법
CN108778273B (zh) 2016-03-07 2022-06-17 默沙东公司 二环芳基单环β-内酰胺化合物及其用于治疗细菌感染的用途的方法
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
CN107641119B (zh) 2016-07-21 2019-11-08 中国科学院上海药物研究所 单环β-内酰胺-铁载体轭合物及其制备方法和用途
US11414411B2 (en) 2017-08-02 2022-08-16 Novartis Ag Chemical process for manufacturing monobactam antibiotic and intermediates thereof
CN111201021B (zh) 2017-10-02 2024-08-23 默沙东有限责任公司 用于治疗细菌感染的苯并二氢吡喃单环β-内酰胺类化合物
US10513504B2 (en) 2018-03-08 2019-12-24 Apotex Inc. Processes for the preparation of apalutamide and intermediates thereof
KR102786898B1 (ko) * 2019-11-22 2025-03-25 쑤저우 얼예 파마슈티칼 컴퍼니 리미티드 설포닐우레아 고리 치환 모노시클릭 β-락탐계 항생제
DK4069691T3 (da) 2019-12-06 2024-10-28 Vertex Pharma Substituerede tetrahydrofuraner som modulatorer af natriumkanaler
CN111303144B (zh) * 2019-12-13 2020-11-27 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
MX2023011616A (es) 2021-03-31 2023-10-30 Fedora Pharmaceuticals Inc Compuestos de lactivicina, su preparacion y uso como agentes antibacterianos.
KR102781293B1 (ko) * 2021-05-07 2025-03-17 한국생명공학연구원 신규 사이드로포어 화합물 및 이를 이용한 금속 나노입자 복합체
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
TWI829432B (zh) 2021-11-18 2024-01-11 美商默沙東有限責任公司 用於治療細菌感染之唍脒單環內醯胺(monobactam)化合物
JP7671398B2 (ja) * 2021-11-18 2025-05-01 メルク・シャープ・アンド・ドーム・エルエルシー クロマンアミジンモノバクタム抗生物質
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CN115304594B (zh) * 2022-10-12 2023-02-14 苏州二叶制药有限公司 磺酰脲环取代的化合物的盐型及其晶型

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01502660A (ja) * 1986-05-23 1989-09-14 ジ・アップジョン・カンパニー N―1置換スルホニルアミノカルボニル、c―4置換モノバクタム類
CA2629570C (en) 2005-12-07 2012-11-27 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
MX2009010407A (es) 2007-03-28 2009-12-01 Apotex Technologies Inc Derivados fluorados de deferiprona.
EP2379546A1 (en) * 2008-12-19 2011-10-26 Pfizer Inc. Monocarbams

Also Published As

Publication number Publication date
JP2013544276A (ja) 2013-12-12
ES2542431T3 (es) 2015-08-05
CA2815821C (en) 2015-07-07
CA2815821A1 (en) 2012-06-07
AU2011336209B2 (en) 2015-03-19
HK1184462A1 (en) 2014-01-24
UY33754A (es) 2012-06-29
CN103228652B (zh) 2015-02-18
EP2646436A1 (en) 2013-10-09
CN103228652A (zh) 2013-07-31
KR20130112054A (ko) 2013-10-11
EP2646436B1 (en) 2015-05-27
ZA201304479B (en) 2014-03-26
WO2012073138A1 (en) 2012-06-07
KR101514587B1 (ko) 2015-04-22
IL226052A0 (en) 2013-06-27
AU2011336209A1 (en) 2013-05-30
DK2646436T3 (en) 2015-06-29
US20150148326A1 (en) 2015-05-28
JP5777725B2 (ja) 2015-09-09
AR084001A1 (es) 2013-04-17
US20120302542A1 (en) 2012-11-29
SG190007A1 (en) 2013-06-28
US20130252935A1 (en) 2013-09-26
TW201247661A (en) 2012-12-01

Similar Documents

Publication Publication Date Title
MX2013005994A (es) Monobactamas.
IN2012DN00692A (enExample)
MX2012001618A (es) Derivados de 5-fluoropirimidinona.
PH12012502138B1 (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
PH12013501780A1 (en) Fluoro-pyridinone derivatives useful as antibacterial agents
MX2013011526A (es) Derivados de isoxazol utiles como agentes antibacteriales .
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
JO3131B1 (ar) مركبات كيميائية
HUE059033T2 (hu) Benzoxaborol-származékok bakteriális fertõzések kezelésére
HRP20180972T1 (hr) Kombinacija fenoksibenzamina i polimiksina e za liječenje mikrobnih infekcija
EP2831069A4 (en) ISOXAZOL-beta-lactamase INHIBITORS
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
MX385616B (es) Inhibidores de cdk
IN2012DN00539A (enExample)
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
PL3443957T3 (pl) Związki i kompozycje stosowane w leczeniu nowotworów
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
IN2012DN00695A (enExample)
UA114417C2 (uk) Інгібітори iap
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
EA201291329A1 (ru) Гетероциклические соединения, их получение и их терапевтическое применение
HRP20190169T1 (hr) Postupci liječenja povećanja tjelesne težine inducirane antipsihoticima
EA201270728A1 (ru) Пуриновые соединения
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
UY33973A (es) Métodos de tratamiento dirigido de degeneración lobular frontotemporal.

Legal Events

Date Code Title Description
FG Grant or registration